Topics:
Breast Cancer • Medical Oncology
How do you approach systemic therapy for locoregional recurrence in a patient with triple negative breast cancer who has previously received anthracycline and taxane based chemotherapy?
Based on the CALOR trial (http://www.ncbi.nlm.nih.gov/pubmed/24439313), adjuvant chemotherapy should be considered, but what regimen is preferred? Is there a role for platinum in this setting? Does BRCA status matter?
Answer from: Medical Oncologist at Academic Institution
The CALOR trial took a pragmatic approach and randomized patients to systemic therapy or not. A specific regimen wasn't specified. If the patient has a known BRCA mutation, I would extrapolate from the first line metastatic setting and use a single agent platinum. Outside of that unique situation, t...
Sign in or Register to read more